Pfizer RSV shot meets goals in trial of high-risk adults under age 60

Pfizer said on Tuesday its
respiratory syncytial virus vaccine Abrysvo was well
tolerated and generated an immune response in higher risk adults
under the age of 60 similar to that in older adults,...

Related Keywords

United Kingdom ,United States ,British ,Americans ,David Boulware ,Iona Munjal ,University Of Minnesota ,Drug Administration ,Reuters ,Pfizer ,Michael Erman Editing ,Bill Berkrot ,Markets ,